Proleukin Aldesleukin: Final Phase III data

In the open-label, international Phase III SILCAAT trial, Proleukin plus antiretroviral therapy significantly increased CD+ T cell counts by 57 cells/mm 3 vs. antiretroviral therapy alone (p<0.001), b...